CRT Meeting

Lumen diameter stenosis and noncalcified plaque volume are the CT features most predictive of MACE in the quantification of coronary CTA by artificial intelligence quantitative CT, CONFIRM-2 trial results show. Read more from TCT 2024 on https://ow.ly/wJa750TVmnP. https://ow.ly/SYIC50TVmnQ

AI-QCT in CONFIRM-2 Study Shows Predictive Features for MACE in Patients With CAD WASHINGTON, DC - Lumen diameter stenosis and noncalcified plaque volume are the computed tomography (CT) features most predictive of major adverse cardiovascular events (MACE) in the quantification of

The bioadaptor proved superior to contemporary drug-eluting stents in patients undergoing PCI, according to the INFINITY-SWEDEHEART trial. Read more from TCT 2024 on CRTonline.org. https://ow.ly/KclW50TVm2B

Superior Clinical Outcomes at 1-Year With Bioadaptor Compared to Drug-Eluting Stents During PCI According to INFINITY-SWEDEHEART Study The bioadaptor proved superior to contemporary drug-eluting stents (DES) in patients undergoing percutaneous coronary intervention (PCI) according to the INFINITY-SWEDEHEART trial, with results presen

In an intention-to-treat and per-protocol analyses, Distal Radial Access’ puncture success rate does not demonstrate non-inferiority to Transradial Access, according to results outlined in the DRAMI Trial. Read more from TCT 2024 on CRTonline.org. https://ow.ly/pLtH50TVlNZ

DRA Puncture Success Rate ‘Not Inferior’ to TRA, Suggest DRAMI Trial Researchers In an intention-to-treat and per-protocol analyses, Distal Radial Access’ (DRA) puncture success rate does not demonstrate non-inferiority to Transradial Access (TRA), according to results outlined in

Innovation and Expertise Meet at ! Join your colleagues March 8-11 at CRT 2025 and experience the latest in interventional cardiology education. Visit CRTmeeting.org to register today!

Pre-treatment with loading-dose heparin upon first medical contact was associated with improved spontaneous reperfusion of infarct‐related artery without increasing the risk of major bleeding, according to the HELP-PCI trial. Read more from TCT 2024 on https://ow.ly/JQle50TVlCP. https://ow.ly/lAaO50TVlCN

Heparin at First Medical Contact Associated with Improved Spontaneous Reperfusion, without Increased Bleeding Risk: HELP-PCI Data Pre-treatment with loading-dose heparin upon first medical contact (FMC) was associated with improved spontaneous reperfusion of infarct‐related artery (IRA) without increasing the risk of major bleed

Side branching with a DCB led to lower MACE rates at 1-year in patients with simple, true coronary bifurcation lesions than noncompliant balloons in the DCB-BIF study. Read more from TCT 2024 on CRTonline.org. https://ow.ly/o3jN50TVkY4

DCB Side Branching Led to Lower 1-Year MACE Rate in True Coronary Bifurcation Lesion Patients: DCB-BIF Study Side branching with a drug-coated balloon (DCB) led to lower major adverse cardiac events (MACE) rate at 1-year in patients with simple, true coronary bifurcation lesions than noncompliant balloons (N

In patients with moderate AS and HFrEF on guideline-directed medical therapy, TAVR was not superior to general AS surveillance for the composite endpoint of the TAVR UNLOAD trial. Read more from TCT 2024 on https://ow.ly/5lYM50TVkEQ. https://ow.ly/l4UO50TVkES

TAVR Not Superior to AS Surveillance in Patients With Moderate AS, HFrEF on GDMT: TAVR UNLOAD Trial WASHINGTON, DC - In patients with moderate aortic stenosis (AS) and heart failure with reduced ejection fraction (HFrEF) on guideline-directed medical therapy, transcatheter aortic valve replacement (

Join us at 7:30 AM ET Wednesday for Cath Conference! Jacqueline Tamis-Holland, MD, will discuss "SCAI Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary PCI." Please email [email protected] if you need a registration link.

In asymptomatic severe AS with evidence of myocardial fibrosis on cardiac MRI, early TAVR did not decrease the composite endpoint of all-cause death and AS-related hospitalization, according to the EVOLVED clinical trial. Read more from TCT 2024 on CRTonline.org. https://www.crtonline.org/news-detail/new-newsrelease-1696

No Benefit in Early TAVR in Asymptomatic Patients with Severe AS and Myocardial Fibrosis: EVOLVED Study In asymptomatic severe aortic stenosis with evidence of myocardial fibrosis on cardiac MRI, early TAVR did not decrease the composite endpoint of all-cause death and aortic stenosis-related hospitaliz

Early TAVR is superior to clinical surveillance in patients with asymptomatic severe AS, results from the EARLY TAVR trial show. Read more from TCT 2024 on CRTonline.org. https://ow.ly/U95650TVjRX

EARLY TAVR Trial Shows Superiority of Early TAVR for Patients With Asymptomatic Severe AS WASHINGTON, DC - Early transcatheter aortic valve replacement (TAVR) is superior to clinical surveillance (CS) in patients with asymptomatic severe aortic stenosis (AS), results from the EARLY TAVR tr

TCT 2024 news coverage is available TODAY! Go to CRTonline.org to check out our news, slides and interviews from the conference. 🫀💙

Make sure you've signed up for CRT Community ahead of TCT 2024 to get the latest news and late-breaking trial coverage! Go to CRTonline.org and sign up today!🫀📖

Did you hear the latest news? Professional Basketball player Caitlin Clark will be the Women & Heart Symposium Keynote Speaker. Don't wait, register today for CRT 2025 at CRTmeeting.org.

Patients hospitalized for COVID-19 are at greater risk for coronary artery disease, and patients with non-O blood types are at an additional risk for post-acute myocardial infarction and stroke, a new analysis from the UK Biobank shows. Read more on CRTonline.

Hospitalized COVID-19 Patients at Greater Risk for CAD, MACE: UK Biobank Analysis Patients hospitalized for COVID-19 are at greater risk for coronary artery disease, and patients with non-O blood types are at an additional risk for post-acute myocardial infarction and stroke, a new

Share your impactful research to improve the field of interventional cardiology at ! Submit your late-breaking trial today at CRTmeeting.org.

Join your colleagues at the Advanced Heart Failure Innovation Summit, March 8 - 9, 2025. Register today at CRTmeeting.org.

Join us at 7:30 AM ET Wednesday for Cath Conference! Jacqueline Tamis-Holland, MD, will discuss "SCAI Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary PCI." Please email [email protected] if you need a registration link.

✨Exciting news!✨ We are thrilled to announce Caitlin Clark, Professional Basketball Player 🏀 as the keynote speaker for our Women & Heart Symposium 💗 👩‍⚕️ at !

Register today at CRTmeeting.org and mark your calendars 📅 for CRT 2025 from March 8-11!

Keynote Speaker🎤 Announcement Coming Soon📣 Any guesses who our next guest is...

*Was a number 1 draft pick
*Has won numerous awards...including Rookie of the Year
*NCAA’s Division-I all-time leading scorer in basketball
*College jersey retired, the 3rd jersey in program history at this university

Join us for 2 Days of Heart Failure programming! Register today at CRTmeeting.org.

Don't wait, the deadline for submitting your Interesting and Challenging Cases for CRT 2025 is Tuesday, December 10, 2024! Go to CRTmeeting.org and submit your case.

External validation of the BRIGHT-4 results shows that patients with STEMI who receive bivalirudin plus a high-dose infusion 2- to 4-hours post-PCI have reduced cardiac mortality and major bleeding, and no increase in ischemic events, compared with patients who receive heparin monotherapy with provisional GPI use.

BRIGHT-4 External Confirmation: Mortality, Bleeding Reduced, no Increase in Ischemic Events, in STEMI Patients Receiving Bivalirudin Plus High-Dose Infusion Post-PCI External validation of the BRIGHT-4 results shows that patients with ST-segment myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) who receive bivalirudin plus

🌟 Register for today! 🌟 Embrace the chance to connect, learn, and lead. Join us in shaping the future of cardiovascular health ❤️‍🩹. Where innovation meets expertise, with 10 focus tracks, there are sessions for everyone! Don’t miss out—be part of the change! 🚀

Visit CRTmeeting.org to secure your spot today 💻

Share your breakthroughs in cardiovascular medicine ❤️🩺 and interventions for the opportunity to educate and inspire others in the field at !

Submissions portal 👉 https://ow.ly/jzz950TJe8X